Kidney disease — all decisions

The Veteran was granted an initial 60 percent evaluation for renal cancer with partial nephrectomy and residuals of chronic kidney disease and voiding dysfunction.

The Board granted an initial rating of 70 percent for PTSD prior to November 7, 2023, and a TDIU due to essential tremors, while denying higher ratings and earlier effective dates for other conditions.

The Board granted service connection for chronic kidney disease and gastroesophageal reflux disease, both as secondary to the Veteran's service-connected myelodysplastic syndrome with fatigue.

The Board remands the claim for service connection of renal cysts due to a pre-decisional duty to assist error and conflicting reports from the VA examiner.

The Board granted service connection for multiple conditions, including diabetes mellitus, type II, coronary artery disease, and various neuropathies and disabilities, effective September 30, 2010, for accrued benefits purposes.

The appeal is remanded to obtain a TERA memorandum and medical opinions addressing the Veteran's claimed conditions, including diabetes mellitus, renal failure, peripheral neuropathy of both lower extremities, and an acquired psychiatric disorder, in relation to his service and exposure to toxic substances.

The Board remands the claim for a secondary service connection for chronic kidney disease, as it finds the November 2023 VA medical examiner's opinion to be inadequate and requires an addendum opinion addressing aggravation.

The Board denied service connection for kidney stones as they were not shown during service, causally or etiologically related to service, and were not caused by or permanently worsened in severity by a service-connected disability.

The Board granted service connection for kidney and bladder cancer, as well as the removal of the left kidney due to a service-connected disability.

The Board remands the claim for service connection for kidney disease, cyst due to inadequate VA examination and failure to provide a TERA examination under the PACT Act.

The Board denied service connection for a kidney cyst, finding no nexus between the Veteran's current condition and his exposure to herbicide agents in service.

The Veteran's service-connected obstructive sleep apnea and chronic kidney disease render him unable to secure or follow a substantially gainful occupation consistent with his education, skill, and training.

The Board remands the claims for service connection for cirrhosis of the liver, status post-transplant, and drug-induced chronic kidney disease, as secondary to liver transplant, due to missing exposure data from Camp Lejeune.

The Board denied the Veteran's claim for an initial compensable rating for chronic kidney disease stage II as there was no evidence of a GFR score of 59 mL/min/1.73 m2 or lower for at least three consecutive months during any 12-month period on appeal.

The Board denied earlier effective dates for the grant of service connection and a higher disability rating, as well as remanded claims related to CUE in prior decisions.

The Board remands the claim for service connection for kidney stones to correct duty to assist errors, including obtaining private treatment records and scheduling a VA examination.

The Board granted service connection for hypertension on a presumptive basis due to in-service herbicide exposure and remanded the claims for stroke and kidney disease for further development.

The Board remands the claim for service connection for a kidney disability, claimed as stage 3 renal failure, due to a pre-decisional duty to assist error regarding an opinion on secondary aggravation.

The Board remands the claims for service connection for various disabilities, including a heart disorder, neck artery disability, leg bypass surgery and residuals thereof, kidney transplant and residuals thereof, and left to right leg artery transplant and residuals thereof, as there has not been substantial compliance with previous remand directives.

The Veteran was granted an initial 100 percent evaluation for cystic kidney disease, clear cell renal cell carcinoma and an effective date of November 29, 2021, but no earlier.